NCT03737994 2026-04-07
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
13 trialsNCT06282991 2026-03-10
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled
Pfizer
Completed
NCT03052608 2025-11-25
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Pfizer
Phase 3 Active not recruiting
NCT03909971 2025-11-05
A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China
Pfizer
Phase 2 Completed
NCT03107988 2025-09-15
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT04362072 2025-06-11
Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer
Pfizer
Phase 4 Completed
NCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT04541706 2024-12-20
Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India
Pfizer
Phase 4 Completed
NCT04753658 2024-09-23
Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib
Pfizer
Terminated
NCT01970865 2024-08-12
A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
Pfizer
Phase 1/2 Completed
NCT03726333 2024-06-21
Hepatic Impairment Study for Lorlatinib in Cancer Patients
Pfizer
Phase 1 Terminated
NCT02584634 2023-07-07
Javelin Lung 101
Pfizer
Phase 1/2 Terminated
NCT04647110 2023-04-06
Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
Pfizer
Completed